Unveiling PAK4 as a Key Biomarker in Adrenocortical Carcinoma: Insights from Bioinformatics and Experimental Evidence

Qiancheng Mao1, Ming Liu1, Xidong Wang1

  • 1Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, 264000 Yantai, Shandong, China.

PubMed
Abstract

Insights

p21-activated kinase 4 (PAK4) is overexpressed in adrenocortical carcinoma (ACC), correlating with poor prognosis and advanced stages. This suggests PAK4 may be a potential therapeutic target and prognostic biomarker for ACC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genomics

Background:

  • Adrenocortical carcinoma (ACC) is a rare, aggressive adrenal cancer with high recurrence rates post-surgery.
  • p21-activated kinase 4 (PAK4) is implicated in various cancers, but its role in ACC is not well understood.

Purpose of the Study:

  • To investigate the expression levels and clinical significance of PAK4 in adrenocortical carcinoma.
  • To explore the potential of PAK4 as a prognostic biomarker and therapeutic target for ACC.

Main Methods:

  • Analysis of PAK4 expression in ACC using Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data.
  • Clinical relevance assessed via survival analysis, Cox regression, ROC curves, and nomograms.
  • Functional enrichment, pathway analysis (GO, KEGG, GSEA), and immune infiltration analysis (TISIDB) were performed. Immunohistochemistry validated findings.

Main Results:

  • PAK4 was significantly upregulated in ACC tissues compared to normal samples (p < 0.05).
  • High PAK4 expression correlated with shorter survival, advanced tumor stage (TNM), and increased malignancy (p < 0.05).
  • PAK4 is linked to the Hedgehog pathway, cell proliferation, and immune cell infiltration, confirmed by immunohistochemistry.

Conclusions:

  • PAK4 is significantly overexpressed in ACC and plays a potential carcinogenic role.
  • PAK4 demonstrates potential as an independent prognostic biomarker and therapeutic target for adrenocortical carcinoma.